신경혈관 혈전 제거 기기 : 시장 동향, 경쟁 구도, 시장 예측(-2032년)

Neurothrombectomy Devices Market Summary

• The global neurothrombectomy devices market is expected to increase from USD 849.70 million in 2024 to USD 1,434.78 million by 2032, reflecting strong and sustained growth.
• The global neurothrombectomy devices market is growing at a CAGR of 6.88% during the forecast period from 2025 to 2032.
• The market of neurothrombectomy devices is being primarily driven by the rising burden of neurological disorders, an increase in cases of hypertension, diabetes, and obesity, technological advancements in the product designs, and an increase in product development activities among the key market players.
• The leading companies operating in the neurothrombectomy devices market include Stryker, Penumbra, Inc., Vesalio, LLC., Acandis GmbH, Rapid Medical, Johnson & Johnson Services Inc., Teleflex Incorporated, Medtronic, NeuroVasc Technologies, Inc., Perflow Medical, Edward LifeSciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroVention Inc., phenox GmbH, Biomedical Solutions Inc., Ceretrieve Ltd., Anaconda Biomed SL, Genesis Medtech, Innova Vascular, and others.
• North America is expected to dominate the neurothrombectomy devices market. This can be ascribed to the increasing prevalence of stroke, obesity, hypertension, diabetes, and others, increased government initiatives coupled with increased awareness programs for neurovascular disease, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of neurovascular thrombectomy devices/neurothrombectomy devices.
• In the product type segment of the neurothrombectomy devices market, the clot retrievers category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Neurothrombectomy Devices Market

• Rising burden of neurological disorders leading to a surge in neurothrombectomy devices: The increasing prevalence of neurological disorders, such as ischemic strokes and aneurysms, is driving a growing demand for neurothrombectomy devices. As more patients require minimally invasive interventions to restore blood flow and prevent long-term neurological damage, healthcare providers are increasingly adopting these advanced devices, boosting their overall market growth.
• Increase in cases of hypertension, diabetes, and obesity, escalating the market of neurothrombectomy devices: The rising incidence of hypertension, diabetes, and obesity, key risk factors for stroke, is fueling the demand for neurothrombectomy devices. As more patients experience cerebrovascular events linked to these conditions, the need for effective, minimally invasive interventions grows, driving market expansion.
• Technological advancement in product design: Technological advancements in neurothrombectomy device design, including improved catheter flexibility, enhanced clot retrieval mechanisms, and real-time imaging integration, are significantly boosting the market. These innovations make procedures safer, faster, and more effective, encouraging wider adoption among healthcare providers and expanding the overall market.

Neurothrombectomy Devices Market Report Segmentation

This neurothrombectomy devices market report offers a comprehensive overview of the global neurothrombectomy devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), End-User (Hospitals, Specialty Centers, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing neurothrombectomy devices market.

Neurovascular thrombectomy devices, also known as cerebral thrombectomy devices, are used to remove or destroy blood clots in the brain region. These devices are also used in patients where pharmacological treatment has not worked effectively.

The rising burden of neurological disorders, particularly stroke, is significantly boosting the market for neurovascular thrombectomy devices, as these are the medical instruments used to remove blood clots from the blood vessels in the brain. Concurrent with this, the rise in cases of hypertension, diabetes, and obesity further exacerbates the risk of stroke and other neurological disorders. These conditions are well-established risk factors for stroke, leading to a higher incidence of acute ischemic events and, consequently, an increased demand for thrombectomy devices. However, the growing awareness and adoption of mechanical thrombectomy devices have further boosted the market. Furthermore, key market players are continuously investing in research and development to introduce innovative neurovascular thrombectomy devices/neurothrombectomy devices, increasing partnerships and collaborations, product launches, and approvals, ensuring that the market remains dynamic and innovative during the forecast period from 2025 to 2032.

What are the latest Neurothrombectomy Devices Market Dynamics and Trends?

The increasing cases of neurological disorders, such as strokes and their associated risk factors, such as diabetes and hypertension, among others, are significantly boosting the overall market for neurothrombectomy devices.

According to the recent data and stats provided by DelveInsight (2025), approximately 46.5 million women and 48.5 million men were stroke survivors.

Additionally, as per the latest data provided by our analyst (2025), approximately 12.5 million new strokes occur each year. Globally, one in four people over age 25 will have a stroke in their lifetime.

The escalating number of stroke cases leads to greater adoption of these devices in hospitals and specialized treatment centers, as they offer a life-saving solution for restoring blood flow. Neurovascular thrombectomy devices, which are designed to remove clots obstructing brain blood vessels, become crucial in managing acute ischemic stroke, a condition where rapid intervention is essential to minimize brain damage and improve patient outcomes. As a result, the surge in stroke cases drives the overall growth of the neurovascular thrombectomy device market, highlighting the critical role these devices play in addressing a major healthcare challenge.

Additionally, as per the data and stats provided by DelveInsight (2024), 1 in 8 people worldwide were living with obesity. Approximately 2.9 billion adults aged 18 years and older were overweight, with 895 million of them living with obesity. Among adults aged 18 years and over, 43.5% were overweight, and 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight. The prevalence of overweight was also significant among older children and adolescents, with over 390 million individuals aged 5-19 years being overweight, including 160 million who were living with obesity.

Obesity is a well-established risk factor for several vascular diseases, including ischemic stroke, which occurs when a blood clot obstructs a blood vessel in the brain. As the global obesity rates rise, there is a corresponding increase in the incidence of stroke and other related complications. This growing patient population drives demand for neurovascular thrombectomy devices, which are used to remove blood clots from the brain and restore normal blood flow, thereby escalating the overall market.

Furthermore, the successful developmental activities in the neurovascular thrombectomy devices/neurothrombectomy devices market further boost the overall market across the globe. For instance, in April 2025, Surmodics, Inc., a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, announced the commercial launch of the Pounce(TM) XL Thrombectomy System, an advanced addition to its Pounce(TM) suite. The system was designed to enable rapid endovascular removal of acute or chronic thrombus from peripheral arteries, further strengthening the company's portfolio in vascular intervention.

Thus, the factors mentioned above are expected to boost the overall market of neurothrombectomy devices during the forecast period from 2025 to 2032.

However, the risk of complications such as vessel perforation, embolism, or damage to surrounding brain tissue, and stringent regulatory concerns for product approval may hinder the future market of neurothrombectomy devices.

Neurothrombectomy Devices Market Segment Analysis

Neurothrombectomy Devices Market Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), End-User (Hospitals, Specialty Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Product Type: Clot Retrievers Category Dominates the Market

Within the product type segment of the neurothrombectomy devices market, clot retrievers are projected to hold the largest share, accounting for an estimated 55% in 2024. Clot retrievers are significantly boosting the overall market of neurovascular thrombectomy devices by revolutionizing the treatment of ischemic strokes. These devices, designed to mechanically remove blood clots from the brain's blood vessels, have enhanced the efficacy of thrombectomy procedures. Their advanced design and functionality enable more effective and reliable clot retrieval, which improves patient outcomes and increases the likelihood of complete recanalization of obstructed vessels. This has led to a broader adoption of thrombectomy as a standard treatment for acute ischemic stroke, thereby driving demand for these devices. The success of clot retrievers has also spurred innovation, leading to the development of newer, more sophisticated models with improved performance characteristics.

Additionally, clinical studies demonstrating the benefits of clot retrievers in reducing disability and mortality have increased their acceptance among healthcare professionals, further contributing to market growth. As more hospitals and stroke centers adopt these technologies, the market for neurovascular thrombectomy devices expands, driven by the increased emphasis on timely and effective stroke intervention.

This growth is also supported by ongoing research and development efforts, and other product development activities across the globe, which continue to refine and enhance clot retrieval technologies, ensuring their continued relevance and effectiveness in stroke care. For instance, in June 2023, Innova Vascular received FDA clearance for two new thrombectomy devices, the Laguna Clot Retriever(TM) System and the Malibu Aspiration Catheter(TM) System. This system is indicated for non-surgical removal of emboli or thrombi, and/or infusing, injecting, or aspirating fluids into or from blood vessels in the peripheral vasculature.

Therefore, owing to the above-mentioned factors, the clot retriever category is expected to generate considerable revenue, thereby pushing the overall growth of the global neurovascular thrombectomy devices/neurothrombectomy devices market during the forecast period.

By Function: Mechanical Non-aspiration Category Dominates the Market

In the function segment of the neurothrombectomy devices market, the mechanical non-aspiration category is estimated to account for the largest market share in 2024, owing to its high efficiency in removing large clots and restoring blood flow in acute ischemic stroke patients. These devices, which include stent retrievers and other clot retrieval systems, are widely preferred by healthcare professionals due to their proven clinical success rates, reduced procedure times, and ability to handle complex occlusions more effectively compared to aspiration-only devices. The growing prevalence of ischemic strokes, coupled with rising demand for minimally invasive and highly effective treatment options, has further driven the adoption of mechanical non-aspiration devices. Additionally, continuous technological advancements in design, such as improved flexibility, navigation, and clot engagement, have enhanced safety and efficacy, making these devices a standard of care in many hospitals and stroke centers. Strong clinical evidence supporting better patient outcomes and increased investment by key market players in product development and approvals are further solidifying the dominance of this segment in the global neurothrombectomy devices market.

By End-User: Hospitals Dominate the Market

The hospital end-user segment is expected to dominate the market, accounting for approximately 70% of the market share in 2024. Hospitals are playing a key role in boosting the neurothrombectomy devices market as they are the primary hubs for stroke care and advanced neurovascular treatments. With the rising incidence of ischemic strokes, these healthcare facilities are increasingly adopting minimally invasive thrombectomy procedures to improve patient outcomes. The availability of skilled neurologists and interventional radiologists, along with investments in advanced imaging and surgical infrastructure, further supports the use of these devices. Additionally, growing patient preference for specialized care in hospitals and clinics ensures higher procedure volumes, thereby accelerating the overall market growth for neurothrombectomy devices.

Neurothrombectomy Devices Market Regional Analysis

North America Neurothrombectomy Devices Market Trends

North America is projected to capture the largest share of the neurothrombectomy devices market in 2024, accounting for approximately 43% of the global market across all regions. This can be ascribed to the increasing prevalence of stroke, obesity, hypertension, diabetes, and others, increased government initiatives coupled with increased awareness programs for neurovascular disease, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of neurovascular thrombectomy devices/neurothrombectomy devices.

According to the latest data provided by the DelveInsight Business Research LLP (2024), in the United States, a stroke occurs every 40 seconds, with more than 799,000 people experiencing a stroke annually. Of these, approximately 620,000 were first or new strokes, while around 187,000, or nearly 1 in 4, involved individuals had a previous stroke. Ischemic strokes, which result from blocked blood flow to the brain, accounted for about 87% of all stroke cases.

Additionally, as per the recent data provided by our analyst (2024), nearly half of the adults in the United States, totaling 116 million, had hypertension, with the majority, 92.1 million, having their condition not under control.

Furthermore, as per the same source (2024), approximately 38.4 million people of all ages, representing 11.6% of the U.S. population, had diabetes.

Diabetes and hypertension are major risk factors for stroke, leading to an increased demand for effective treatments to manage and mitigate these risks. Neurovascular thrombectomy devices, which are used to remove blood clots from the brain's blood vessels, become increasingly critical as the incidence of stroke rises. This growing demand for thrombectomy procedures drives the market for these devices, as healthcare providers seek advanced tools to enhance patient outcomes and reduce the impact of strokes. Consequently, the prevalence of diabetes and hypertension directly contributes to the market expansion of neurovascular thrombectomy devices across the region.

Moreover, the increase in product development activities and ongoing research and development further escalates the market of neurovascular thrombectomy devices/neurothrombectomy devices across the region. For instance, in February 2024, Innova Vascular announced the successful early commercial use of the Laguna Thrombectomy System(TM) in patients.

Therefore, the above-mentioned factors are expected to bolster the growth of the neurothrombectomy devices market in North America during the forecast period.

Europe Neurothrombectomy Devices Market Trends

Europe is driving the growth of the neurothrombectomy devices market due to its well-established healthcare infrastructure, rising prevalence of stroke cases, and strong focus on early diagnosis and treatment of neurological disorders. According to DelveInsight's estimates (2025), around 1.5 million people living in the UK have survived a stroke or transient ischaemic attack (TIA), thereby boosting the overall market of neurothrombectomy devices, as these devices offer a life-saving solution for restoring blood flow.

Additionally, the region benefits from supportive government initiatives, increased healthcare spending, and widespread adoption of advanced medical technologies. Additionally, the presence of leading medical device manufacturers, growing clinical research activities, and expanding access to minimally invasive stroke treatments further contribute to Europe's significant role in accelerating the market's growth.

Asia-Pacific Neurothrombectomy Devices Market Trends

The Asia-Pacific region is emerging as a key growth driver in the neurothrombectomy devices market due to the rising burden of stroke cases, increasing prevalence of risk factors such as diabetes, hypertension, and obesity, and growing awareness about advanced treatment options. Rapid improvements in healthcare infrastructure, coupled with government initiatives to enhance access to stroke care, are further fueling the adoption of these devices. Moreover, the region's expanding aging population, rising investments in healthcare technology, and greater availability of skilled healthcare professionals are creating strong growth opportunities for neurothrombectomy devices in the Asia-Pacific.

Who are the major players in the neurothrombectomy devices market?

The following are the leading companies in the neurothrombectomy devices market. These companies collectively hold the largest market share and dictate industry trends.

• Stryker
• Penumbra, Inc.
• Vesalio, LLC.
• Acandis GmbH
• Rapid Medical
• Johnson & Johnson Services Inc.
• Teleflex Incorporated
• Medtronic
• NeuroVasc Technologies, Inc.
• Perflow Medical
• Edward LifeSciences Corporation
• Terumo Corporation
• Koninklijke Philips N.V.
• MicroVention Inc.
• phenox GmbH
• Biomedical Solutions Inc.
• Ceretrieve Ltd.
• Anaconda Biomed SL
• Genesis Medtech
• Innova Vascular
• Others

How is the competitive landscape shaping the neurothrombectomy devices market?

The competitive landscape of the neurothrombectomy devices market is shaped by a mix of established global players and emerging innovators, creating a moderately concentrated market. Leading companies dominate with strong product portfolios, advanced technologies, and extensive distribution networks, while smaller firms are contributing through specialized innovations and niche solutions. Strategic activities such as mergers, acquisitions, partnerships, and product launches are intensifying competition as companies aim to expand their market presence and strengthen clinical outcomes. This concentration of expertise and resources not only drives technological advancements but also ensures wider accessibility of neurothrombectomy devices across developed and emerging markets.

Recent Developmental Activities in the Neurothrombectomy Devices Market

• In July 2025, Imperative Care received FDA 510(k) clearance for its Zoom 7X catheter and has a broader Zoom System portfolio for revascularization in acute ischemic stroke.
• In July 2024, Vesalio launched its NeVa NET 4.0 mm device for acute ischemic stroke caused by large vessel occlusion. This device is an addition to its existing portfolio and features an integrated micro-filter to prevent clot escape.
• In February 2024, Johnson & Johnson's CERENOVUS introduced this new intermediate catheter, which uses "TruCourse" technology to improve navigation and revascularization procedures in stroke patients.
• In February 2023, Phenox Inc. received FDA 510(k) clearance for its pRESET(R) Thrombectomy Device, a minimally invasive tool designed to remove blood clots in patients with acute ischemic stroke. This minimally invasive device is designed to effectively remove blood clots from blocked brain arteries, helping to rapidly restore blood flow and minimize brain damage.

Neurothrombectomy Devices Market Segmentation

• Neurothrombectomy Devices by Product Type Exposure
• Clot Retrievers
• Stent Retrievers
• Aspiration Devices
• Others
• Neurothrombectomy Devices Function Exposure
• Mechanical Non-aspiration
• Mechanical Aspiration
• Neurothrombectomy Devices End-Users Exposure
• Hospitals
• Specialty Centers
• Others
• Neurothrombectomy Devices Geography Exposure
• North America Neurothrombectomy Devices Market
• United States Neurothrombectomy Devices Market
• Canada Neurothrombectomy Devices Market
• Mexico Neurothrombectomy Devices Market
• Europe Neurothrombectomy Devices Market
• United Kingdom Neurothrombectomy Devices Market
• Germany Neurothrombectomy Devices Market
• France Neurothrombectomy Devices Market
• Italy Neurothrombectomy Devices Market
• Spain Neurothrombectomy Devices Market
• Rest of Europe Neurothrombectomy Devices Market
• Asia-Pacific Neurothrombectomy Devices Market
• China Neurothrombectomy Devices Market
• Japan Neurothrombectomy Devices Market
• India Neurothrombectomy Devices Market
• Australia Neurothrombectomy Devices Market
• South Korea Neurothrombectomy Devices Market
• Rest of Asia-Pacific Neurothrombectomy Devices Market
• Rest of the World Neurothrombectomy Devices Market
• South America Neurothrombectomy Devices Market
• Middle East Neurothrombectomy Devices Market
• Africa Neurothrombectomy Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are transforming neurothrombectomy devices by enhancing diagnosis, decision-making, and procedural efficiency in stroke care. Advanced AI algorithms integrated with imaging platforms can rapidly detect large vessel occlusions, assess clot characteristics, and prioritize patients for intervention, significantly reducing treatment delays. During procedures, AI-driven navigation tools assist clinicians with real-time guidance, improving catheter placement and retrieval accuracy. Additionally, AI-enabled data analytics help optimize device performance, predict patient outcomes, and personalize treatment strategies. These applications not only improve first-pass success rates and clinical outcomes but also expand access to timely stroke interventions, making AI a critical driver of innovation in the neurothrombectomy devices market.

U.S. Tariff Impact Analysis on Neurothrombectomy Devices Market:

The U.S. tariff impact on the neurothrombectomy devices market is relatively moderate but carries important implications for cost structures and adoption trends across healthcare facilities. Since a significant portion of these devices is manufactured and imported from Europe and Asia, tariffs and trade regulations can elevate procurement and distribution expenses, adding pressure on hospitals, clinics, and distributors to manage higher operating costs. Larger hospitals and comprehensive stroke centers, which see a high volume of acute stroke cases, are generally able to absorb these additional expenses due to the critical need for timely neurothrombectomy interventions. However, smaller healthcare providers and rural facilities may find it more challenging, potentially leading to disparities in access to advanced devices. In some cases, tariffs may also encourage U.S.-based companies to increase domestic production or form localized partnerships to mitigate reliance on imports, which could gradually shift market dynamics. Despite these hurdles, the life-saving nature of neurothrombectomy devices ensures that their adoption remains a clinical priority, meaning tariffs influence pricing strategies and purchasing decisions but are unlikely to significantly reduce overall demand in the U.S. market.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Neurothrombectomy Devices market report study

• Market size analysis for the current neurothrombectomy devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the neurothrombectomy devices market.
• Various opportunities available for the other competitors in the neurothrombectomy devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current neurothrombectomy devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the neurothrombectomy devices market growth in the future?

Frequently Asked Questions for the Neurothrombectomy Devices Market

1. What is the growth rate of the neurothrombectomy devices market?

• The neurothrombectomy devices market is estimated to grow at a CAGR of 6.88% during the forecast period from 2025 to 2032.

2. What is the market for neurothrombectomy devices?

• The neurothrombectomy devices market was valued at USD 849.70 million in 2024, and is expected to reach USD 1,434.78 million by 2032.

3. Which region has the highest share in the neurothrombectomy devices market?

• North America is expected to dominate the neurothrombectomy devices market. This can be ascribed to the increasing prevalence of stroke, obesity, hypertension, diabetes, and others, increased government initiatives coupled with increased awareness programs for neurovascular disease, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of neurovascular thrombectomy devices/neurothrombectomy devices.

4. What are the drivers for the neurothrombectomy devices market?

• The rising burden of neurological disorders, particularly stroke, is significantly boosting the market for neurovascular thrombectomy devices, as these are the medical instruments used to remove blood clots from the blood vessels in the brain. Concurrent with this, the rise in cases of hypertension, diabetes, and obesity further exacerbates the risk of stroke and other neurological disorders. These conditions are well-established risk factors for stroke, leading to a higher incidence of acute ischemic events and, consequently, an increased demand for thrombectomy devices. However, the growing awareness and adoption of mechanical thrombectomy devices have further boosted the market. Furthermore, key market players are continuously investing in research and development to introduce innovative neurovascular thrombectomy devices/neurothrombectomy devices, increasing partnerships and collaborations, product launches, and approvals, ensuring that the market remains dynamic and innovative during the forecast period from 2025 to 2032.

5. Who are the key players operating in the neurothrombectomy devices market?

• Some of the key market players operating in the Neurothrombectomy Devices market include Stryker, Penumbra, Inc., Vesalio, LLC., Acandis GmbH, Rapid Medical, Johnson & Johnson Services Inc., Teleflex Incorporated, Medtronic, NeuroVasc Technologies, Inc., Perflow Medical, Edward LifeSciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroVention Inc., phenox GmbH, Biomedical Solutions Inc., Ceretrieve Ltd., Anaconda Biomed SL, Genesis Medtech, Innova Vascular, and others.

Table of Contents

1. Neurothrombectomy Devices Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Neurothrombectomy Devices Market Executive Summary

• 2.1 Market at Glance

3. Neurothrombectomy Devices Market Key Factors Analysis

• 3.1 Neurothrombectomy Devices Market Drivers
  • 3.1.1 Rising burden of neurological disorders
  • 3.1.2 Increase in cases of hypertension, diabetes, and obesity
  • 3.1.3 Increase in technological advancement
  • 3.1.4 Increase in product development activities among the key market players
• 3.2 Neurothrombectomy Devices Market Restraints and Challenges
  • 3.2.1 Risk of complications such as vessel perforation, embolism, or damage to surrounding brain tissue
  • 3.2.2 Stringent regulatory requirements for product approval
• 3.3 Neurothrombectomy Devices Market Opportunity
  • 3.3.1 Ongoing research and development in improving clot retrieval mechanisms and enhancing imaging integration

4. Impact Analysis

• 4.1 AI-Powered Innovations and Applications
• 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

• 5.1 The United States
• 5.2 Europe
• 5.3 Japan
• 5.4 China

6. Neurothrombectomy Devices Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Neurothrombectomy Devices Market Assessment

• 7.1 By Product Type
  • 7.1.1 Clot Retrievers
  • 7.1.2 Stent Retrievers
  • 7.1.3 Aspiration Devices
  • 7.1.4 Others
• 7.2 By Function
  • 7.2.1 Mechanical Non-aspiration
  • 7.2.2 Mechanical Aspiration
• 7.3 By End-Users
  • 7.3.1 Hospitals
  • 7.3.2 Specialty Centers
  • 7.3.3 Others
• 7.4 By Geography
  • 7.4.1 North America
    • 7.4.1.1 United States Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.1.2 Canada Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.1.3 Mexico Neurothrombectomy Devices Market Size in USD million (2022-2032)
  • 7.4.2 Europe
    • 7.4.2.1 France Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.2.2 Germany Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.2.3 United Kingdom Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.2.4 Italy Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.2.5 Spain Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.2.6 Rest of Europe Neurothrombectomy Devices Market Size in USD million (2022-2032)
  • 7.4.3 Asia-Pacific
    • 7.4.3.1 China Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.3.2 Japan Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.3.3 India Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.3.4 Australia Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.3.5 South Korea Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.3.6 Rest of Asia-Pacific Neurothrombectomy Devices Market Size in USD million (2022-2032)
  • 7.4.4 Rest of the World (RoW)
    • 7.4.4.1 Middle East Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.4.2 Africa Neurothrombectomy Devices Market Size in USD million (2022-2032)
    • 7.4.4.3 South America Neurothrombectomy Devices Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Neurothrombectomy Devices Market Company and Product Profiles

• 10.1 Stryker
  • 10.1.1 Company Overview
  • 10.1.2 Company Snapshot
  • 10.1.3 Financial Overview
  • 10.1.4 Product Listing
  • 10.1.5 Entropy
• 10.2 Penumbra, Inc.
  • 10.2.1 Company Overview
  • 10.2.2 Company Snapshot
  • 10.2.3 Financial Overview
  • 10.2.4 Product Listing
  • 10.2.5 Entropy
• 10.3 Vesalio, LLC.
  • 10.3.1 Company Overview
  • 10.3.2 Company Snapshot
  • 10.3.3 Financial Overview
  • 10.3.4 Product Listing
  • 10.3.5 Entropy
• 10.4 Acandis GmbH
  • 10.4.1 Company Overview
  • 10.4.2 Company Snapshot
  • 10.4.3 Financial Overview
  • 10.4.4 Product Listing
  • 10.4.5 Entropy
• 10.5 Rapid Medical
  • 10.5.1 Company Overview
  • 10.5.2 Company Snapshot
  • 10.5.3 Financial Overview
  • 10.5.4 Product Listing
  • 10.5.5 Entropy
• 10.6 Johnson & Johnson Services Inc.
  • 10.6.1 Company Overview
  • 10.6.2 Company Snapshot
  • 10.6.3 Financial Overview
  • 10.6.4 Product Listing
  • 10.6.5 Entropy
• 10.7 Teleflex Incorporated
  • 10.7.1 Company Overview
  • 10.7.2 Company Snapshot
  • 10.7.3 Financial Overview
  • 10.7.4 Product Listing
  • 10.7.5 Entropy
• 10.8 Medtronic
  • 10.8.1 Company Overview
  • 10.8.2 Company Snapshot
  • 10.8.3 Financial Overview
  • 10.8.4 Product Listing
  • 10.8.5 Entropy
• 10.9 NeuroVasc Technologies, Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Snapshot
  • 10.9.3 Financial Overview
  • 10.9.4 Product Listing
  • 10.9.5 Entropy
• 10.10 Perflow Medical
  • 10.10.1 Company Overview
  • 10.10.2 Company Snapshot
  • 10.10.3 Financial Overview
  • 10.10.4 Product Listing
  • 10.10.5 Entropy
• 10.11 Edward LifeSciences Corporation
  • 10.11.1 Company Overview
  • 10.11.2 Company Snapshot
  • 10.11.3 Financial Overview
  • 10.11.4 Product Listing
  • 10.11.5 Entropy
• 10.12 Terumo Corporation
  • 10.12.1 Company Overview
  • 10.12.2 Company Snapshot
  • 10.12.3 Financial Overview
  • 10.12.4 Product Listing
  • 10.12.5 Entropy
• 10.13 Koninklijke Philips N.V.
  • 10.13.1 Company Overview
  • 10.13.2 Company Snapshot
  • 10.13.3 Financial Overview
  • 10.13.4 Product Listing
  • 10.13.5 Entropy
• 10.14 MicroVention Inc.
  • 10.14.1 Company Overview
  • 10.14.2 Company Snapshot
  • 10.14.3 Financial Overview
  • 10.14.4 Product Listing
  • 10.14.5 Entropy
• 10.15 phenox GmbH
  • 10.15.1 Company Overview
  • 10.15.2 Company Snapshot
  • 10.15.3 Financial Overview
  • 10.15.4 Product Listing
  • 10.15.5 Entropy
• 10.16 Biomedical Solutions Inc.
  • 10.16.1 Company Overview
  • 10.16.2 Company Snapshot
  • 10.16.3 Financial Overview
  • 10.16.4 Product Listing
  • 10.16.5 Entropy
• 10.17 Ceretrieve Ltd.
  • 10.17.1 Company Overview
  • 10.17.2 Company Snapshot
  • 10.17.3 Financial Overview
  • 10.17.4 Product Listing
  • 10.17.5 Entropy
• 10.18 Anaconda Biomed SL
  • 10.18.1 Company Overview
  • 10.18.2 Company Snapshot
  • 10.18.3 Financial Overview
  • 10.18.4 Product Listing
  • 10.18.5 Entropy
• 10.19 Genesis Medtech
  • 10.19.1 Company Overview
  • 10.19.2 Company Snapshot
  • 10.19.3 Financial Overview
  • 10.19.4 Product Listing
  • 10.19.5 Entropy
• 10.20 Innova Vascular
  • 10.20.1 Company Overview
  • 10.20.2 Company Snapshot
  • 10.20.3 Financial Overview
  • 10.20.4 Product Listing
  • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us